MedTrace Logo

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

NCT00675350 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-05-12

No results posted yet for this study

Summary

PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Conditions

  • Hematologic Tumors

Interventions

DRUG

Omacetaxine

1.25 mg/m2 subcutaneous twice daily for 14 days

Sponsors & Collaborators

  • ChemGenex Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • John Nemunaitis, M.D. · Mary Crowley Cancer Research Center

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-09-30
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00675350 on ClinicalTrials.gov